Chemotherapy of secondary leukemias

Giuseppe Visani, Livio Pagano, Alessandro Pulsoni, Patrizia Tosi, Pier Paolo Piccaluga, Rocco Pastano, Tiziana Grafone, Michele Malagola, Alessandro Isidori, Sante Tura

Research output: Contribution to journalArticle

Abstract

Chemotherapy of secondary leukemias is currently still considered to be associated with poor results. However, recent data suggest that the response to remission induction may substantially differ according to the previous medical history of the patients. Therapy related leukemia, arising following exposure to previous alkylating agents or radiotherapy, is often associated with chromosomal abnormalities involving chromosomes 5 and 7 and has a particularly bad response, whereas AML after exposure to epipodophyllotoxins or topoisomerase-II active agents could have a somewhat better response. Acute promyelocytic leukemia secondary to treatment of a primary malignant neoplasm seems to be associated with a better response if compared to other cytotypes of AML or to AML arising after transformation of myelodysplasia. However, here the literature data are not in full agreement, as different kinds of approaches have been applied. In fact, even if the problems encountered in treating patients with secondary leukemia are similar to those seen in patients with AML arising in a background of myelodysplasia (resistant disease and prolonged cytopenia after treatment), there are data suggesting that the use of high dose ara-C, with or without fludarabine, can circumvent resistance in a small but significant number of cases. One of the unsolved problems which still remains is how to consolidate the CR induced with high dose ara-C or with cycles based on anthracycline derivatives. In addition, another question relates to the categories of patients in whom chemotherapy may change the expected survival. Intensive post-remission chemotherapy, with or without autologous HSCT, may constitute an appropriate alternative for patients lacking a suitable sibling donor or for older patients who are in remission after chemotherapy and also able to tolerate other cycles of intensive chemotherapy. In this respect, the specific cytogenetic abnormality involved should be considered the most important prognostic factor for response and disease free survival; patients with abnormalities of chromosome 5 and 7 have a particularly low possibility of response and duration of CR. Furthermore, it is still debatable whether patients, especially the elderly, with these characteristics should go through a series of conventional treatments or just receive supportive treatment. On the other hand, patients with better prognostic factors should be entitled to further intensive treatments, taking into account possible delayed recovery and/or possible less successful collection of peripheral or marrow stem cells.

Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalLeukemia and Lymphoma
Volume37
Issue number5-6
Publication statusPublished - 2000

Fingerprint

Leukemia
Drug Therapy
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Cytarabine
Chromosome Aberrations
Therapeutics
Podophyllotoxin
Remission Induction
Type II DNA Topoisomerase
Acute Promyelocytic Leukemia
Alkylating Agents
Anthracyclines
Disease-Free Survival
Siblings
Radiotherapy
Stem Cells
Bone Marrow
History
Tissue Donors

Keywords

  • Chemotherapy
  • Cytogenetics
  • Leukemia
  • Secondary

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Visani, G., Pagano, L., Pulsoni, A., Tosi, P., Piccaluga, P. P., Pastano, R., ... Tura, S. (2000). Chemotherapy of secondary leukemias. Leukemia and Lymphoma, 37(5-6), 543-549.

Chemotherapy of secondary leukemias. / Visani, Giuseppe; Pagano, Livio; Pulsoni, Alessandro; Tosi, Patrizia; Piccaluga, Pier Paolo; Pastano, Rocco; Grafone, Tiziana; Malagola, Michele; Isidori, Alessandro; Tura, Sante.

In: Leukemia and Lymphoma, Vol. 37, No. 5-6, 2000, p. 543-549.

Research output: Contribution to journalArticle

Visani, G, Pagano, L, Pulsoni, A, Tosi, P, Piccaluga, PP, Pastano, R, Grafone, T, Malagola, M, Isidori, A & Tura, S 2000, 'Chemotherapy of secondary leukemias', Leukemia and Lymphoma, vol. 37, no. 5-6, pp. 543-549.
Visani G, Pagano L, Pulsoni A, Tosi P, Piccaluga PP, Pastano R et al. Chemotherapy of secondary leukemias. Leukemia and Lymphoma. 2000;37(5-6):543-549.
Visani, Giuseppe ; Pagano, Livio ; Pulsoni, Alessandro ; Tosi, Patrizia ; Piccaluga, Pier Paolo ; Pastano, Rocco ; Grafone, Tiziana ; Malagola, Michele ; Isidori, Alessandro ; Tura, Sante. / Chemotherapy of secondary leukemias. In: Leukemia and Lymphoma. 2000 ; Vol. 37, No. 5-6. pp. 543-549.
@article{2adf8e78031b48a49c5dc32d78b4559f,
title = "Chemotherapy of secondary leukemias",
abstract = "Chemotherapy of secondary leukemias is currently still considered to be associated with poor results. However, recent data suggest that the response to remission induction may substantially differ according to the previous medical history of the patients. Therapy related leukemia, arising following exposure to previous alkylating agents or radiotherapy, is often associated with chromosomal abnormalities involving chromosomes 5 and 7 and has a particularly bad response, whereas AML after exposure to epipodophyllotoxins or topoisomerase-II active agents could have a somewhat better response. Acute promyelocytic leukemia secondary to treatment of a primary malignant neoplasm seems to be associated with a better response if compared to other cytotypes of AML or to AML arising after transformation of myelodysplasia. However, here the literature data are not in full agreement, as different kinds of approaches have been applied. In fact, even if the problems encountered in treating patients with secondary leukemia are similar to those seen in patients with AML arising in a background of myelodysplasia (resistant disease and prolonged cytopenia after treatment), there are data suggesting that the use of high dose ara-C, with or without fludarabine, can circumvent resistance in a small but significant number of cases. One of the unsolved problems which still remains is how to consolidate the CR induced with high dose ara-C or with cycles based on anthracycline derivatives. In addition, another question relates to the categories of patients in whom chemotherapy may change the expected survival. Intensive post-remission chemotherapy, with or without autologous HSCT, may constitute an appropriate alternative for patients lacking a suitable sibling donor or for older patients who are in remission after chemotherapy and also able to tolerate other cycles of intensive chemotherapy. In this respect, the specific cytogenetic abnormality involved should be considered the most important prognostic factor for response and disease free survival; patients with abnormalities of chromosome 5 and 7 have a particularly low possibility of response and duration of CR. Furthermore, it is still debatable whether patients, especially the elderly, with these characteristics should go through a series of conventional treatments or just receive supportive treatment. On the other hand, patients with better prognostic factors should be entitled to further intensive treatments, taking into account possible delayed recovery and/or possible less successful collection of peripheral or marrow stem cells.",
keywords = "Chemotherapy, Cytogenetics, Leukemia, Secondary",
author = "Giuseppe Visani and Livio Pagano and Alessandro Pulsoni and Patrizia Tosi and Piccaluga, {Pier Paolo} and Rocco Pastano and Tiziana Grafone and Michele Malagola and Alessandro Isidori and Sante Tura",
year = "2000",
language = "English",
volume = "37",
pages = "543--549",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "5-6",

}

TY - JOUR

T1 - Chemotherapy of secondary leukemias

AU - Visani, Giuseppe

AU - Pagano, Livio

AU - Pulsoni, Alessandro

AU - Tosi, Patrizia

AU - Piccaluga, Pier Paolo

AU - Pastano, Rocco

AU - Grafone, Tiziana

AU - Malagola, Michele

AU - Isidori, Alessandro

AU - Tura, Sante

PY - 2000

Y1 - 2000

N2 - Chemotherapy of secondary leukemias is currently still considered to be associated with poor results. However, recent data suggest that the response to remission induction may substantially differ according to the previous medical history of the patients. Therapy related leukemia, arising following exposure to previous alkylating agents or radiotherapy, is often associated with chromosomal abnormalities involving chromosomes 5 and 7 and has a particularly bad response, whereas AML after exposure to epipodophyllotoxins or topoisomerase-II active agents could have a somewhat better response. Acute promyelocytic leukemia secondary to treatment of a primary malignant neoplasm seems to be associated with a better response if compared to other cytotypes of AML or to AML arising after transformation of myelodysplasia. However, here the literature data are not in full agreement, as different kinds of approaches have been applied. In fact, even if the problems encountered in treating patients with secondary leukemia are similar to those seen in patients with AML arising in a background of myelodysplasia (resistant disease and prolonged cytopenia after treatment), there are data suggesting that the use of high dose ara-C, with or without fludarabine, can circumvent resistance in a small but significant number of cases. One of the unsolved problems which still remains is how to consolidate the CR induced with high dose ara-C or with cycles based on anthracycline derivatives. In addition, another question relates to the categories of patients in whom chemotherapy may change the expected survival. Intensive post-remission chemotherapy, with or without autologous HSCT, may constitute an appropriate alternative for patients lacking a suitable sibling donor or for older patients who are in remission after chemotherapy and also able to tolerate other cycles of intensive chemotherapy. In this respect, the specific cytogenetic abnormality involved should be considered the most important prognostic factor for response and disease free survival; patients with abnormalities of chromosome 5 and 7 have a particularly low possibility of response and duration of CR. Furthermore, it is still debatable whether patients, especially the elderly, with these characteristics should go through a series of conventional treatments or just receive supportive treatment. On the other hand, patients with better prognostic factors should be entitled to further intensive treatments, taking into account possible delayed recovery and/or possible less successful collection of peripheral or marrow stem cells.

AB - Chemotherapy of secondary leukemias is currently still considered to be associated with poor results. However, recent data suggest that the response to remission induction may substantially differ according to the previous medical history of the patients. Therapy related leukemia, arising following exposure to previous alkylating agents or radiotherapy, is often associated with chromosomal abnormalities involving chromosomes 5 and 7 and has a particularly bad response, whereas AML after exposure to epipodophyllotoxins or topoisomerase-II active agents could have a somewhat better response. Acute promyelocytic leukemia secondary to treatment of a primary malignant neoplasm seems to be associated with a better response if compared to other cytotypes of AML or to AML arising after transformation of myelodysplasia. However, here the literature data are not in full agreement, as different kinds of approaches have been applied. In fact, even if the problems encountered in treating patients with secondary leukemia are similar to those seen in patients with AML arising in a background of myelodysplasia (resistant disease and prolonged cytopenia after treatment), there are data suggesting that the use of high dose ara-C, with or without fludarabine, can circumvent resistance in a small but significant number of cases. One of the unsolved problems which still remains is how to consolidate the CR induced with high dose ara-C or with cycles based on anthracycline derivatives. In addition, another question relates to the categories of patients in whom chemotherapy may change the expected survival. Intensive post-remission chemotherapy, with or without autologous HSCT, may constitute an appropriate alternative for patients lacking a suitable sibling donor or for older patients who are in remission after chemotherapy and also able to tolerate other cycles of intensive chemotherapy. In this respect, the specific cytogenetic abnormality involved should be considered the most important prognostic factor for response and disease free survival; patients with abnormalities of chromosome 5 and 7 have a particularly low possibility of response and duration of CR. Furthermore, it is still debatable whether patients, especially the elderly, with these characteristics should go through a series of conventional treatments or just receive supportive treatment. On the other hand, patients with better prognostic factors should be entitled to further intensive treatments, taking into account possible delayed recovery and/or possible less successful collection of peripheral or marrow stem cells.

KW - Chemotherapy

KW - Cytogenetics

KW - Leukemia

KW - Secondary

UR - http://www.scopus.com/inward/record.url?scp=0034048889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034048889&partnerID=8YFLogxK

M3 - Article

C2 - 11042514

AN - SCOPUS:0034048889

VL - 37

SP - 543

EP - 549

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -